{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:28:22Z","timestamp":1786735702500,"version":"build-2736575974"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asian J Androl"],"published-print":{"date-parts":[[2019]]},"DOI":"10.4103\/aja.aja_95_18","type":"journal-article","created":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T06:06:08Z","timestamp":1561701968000},"page":"115","source":"Crossref","is-referenced-by-count":4,"title":["The current status of hormone treatment for prostate cancer patients in Korean real-world practice: a multi-institutional observational study"],"prefix":"10.4103","volume":"21","author":[{"given":"Seok-Soo","family":"Byun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JungKwon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JungJun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TaekWon","family":"Gang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TaeKyun","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HongSup","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SeungChul","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Shin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Yeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SeokJoong","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youn-Soo","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JinSeon","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KwanJoong","family":"Joo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Hoo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/1008-682X.248809-1","first-page":"8225\u201331","volume-title":"Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate","author":"Ryan","year":"2005","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.248809-2","first-page":"162\u201371","volume-title":"Survival of Korean adult cancer patients by stage at diagnosis, 2006-2010: national cancer registry study","author":"Jung","year":"2013","journal-title":"Cancer Res Treat"},{"key":"key-10.4103\/1008-682X.248809-3","first-page":"981\u20139","volume-title":"National practice patterns and time trends in androgen ablation for localized prostate cancer","author":"Cooperberg","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"key-10.4103\/1008-682X.248809-4","first-page":"11\u201325","volume-title":"Contemporary role of androgen deprivation therapy for prostate cancer","author":"Pagliarulo","year":"2012","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.248809-5","first-page":"1066\u201373","volume-title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomized study","author":"Bolla","year":"2010","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/1008-682X.248809-6","first-page":"4406\u201313","volume-title":"Impact of androgen deprivation on physical well-being in patients with prostate cancer: analysis from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry","author":"Sadetsky","year":"2011","journal-title":"Cancer"},{"key":"key-10.4103\/1008-682X.248809-7","first-page":"4448\u201356","volume-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.248809-8","first-page":"3448\u201356","volume-title":"Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the population-based PCBaSe Sweden","author":"Van","year":"2010","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.248809-9","first-page":"1285\u201391","volume-title":"Rising prostate cancer rates in South Korea","author":"Park","year":"2006","journal-title":"Prostate"},{"key":"key-10.4103\/1008-682X.248809-10","first-page":"726\u20139","volume-title":"Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm","author":"Oefelein","year":"2000","journal-title":"J Urol"},{"key":"key-10.4103\/1008-682X.248809-11","unstructured":"World Health Organization. Conceptual framework for the International Classification for Patient Safety. Version 1.1. Final technical report. World Health Organization; 2009. Available from: http:\/\/www.who.int\/patientsafety\/implementation\/taxonomy\/icps_technical_report_en.pdf. [Last accessed on 2018 Sep 28]."},{"key":"key-10.4103\/1008-682X.248809-12","first-page":"1245\u201350","volume-title":"Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors","author":"Szymanski","year":"2010","journal-title":"Urology"},{"key":"key-10.4103\/1008-682X.248809-13","first-page":"1151\u20136","volume-title":"Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT","author":"Klotz","year":"2015","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.248809-14","first-page":"447\u201353","volume-title":"Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: a solid biodegradable leuprorelin implant versus other formulations","author":"Merseburger","year":"2015","journal-title":"J Comp Eff Res"},{"key":"key-10.4103\/1008-682X.248809-15","first-page":"80\u20139","volume-title":"Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy","author":"Iannazzo","year":"2011","journal-title":"Value Health"},{"key":"key-10.4103\/1008-682X.248809-16","unstructured":"Drug Search, Korea Research-Based Pharmaceutical Industry Association. Seoul; 2009. Available from: http:\/\/www.krpia.or.kr\/medicine\/mediinfo.asp. [Last accessed on 2018 Sep 12]."},{"key":"key-10.4103\/1008-682X.248809-17","first-page":"361\u201376","volume-title":"Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma","author":"Samson","year":"2002","journal-title":"Cancer"},{"key":"key-10.4103\/1008-682X.248809-18","first-page":"194\u2013201","volume-title":"Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients","author":"Usami","year":"2007","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"key-10.4103\/1008-682X.248809-19","first-page":"20\u20138","volume-title":"Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients","author":"Akaza","year":"2004","journal-title":"Jpn J Clin Oncol"},{"key":"key-10.4103\/1008-682X.248809-20","first-page":"117\u201382","volume-title":"A re-assessment of the role of combined androgen blockade for advanced prostate cancer","author":"Klotz","year":"2004","journal-title":"BJU Int"},{"key":"key-10.4103\/1008-682X.248809-21","first-page":"1491\u20138","volume-title":"Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials","author":"Prostate","year":"2000","journal-title":"Lancet"},{"key":"key-10.4103\/1008-682X.248809-22","first-page":"1305\u20138","volume-title":"Insulin sensitivity during combined androgen blockade for prostate cancer","author":"Smith","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/1008-682X.248809-23","first-page":"833\u201340","volume-title":"Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology","author":"Levine","year":"2010","journal-title":"Circulation"},{"key":"key-10.4103\/1008-682X.248809-24","first-page":"2361\u20137","volume-title":"Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy","author":"Berruti","year":"2002","journal-title":"J Urol"},{"key":"key-10.4103\/1008-682X.248809-25","first-page":"543\u20138","volume-title":"Androgen deprivation therapy: evidence-based management of side effects","author":"Ahmadi","year":"2013","journal-title":"BJU Int"},{"key":"key-10.4103\/1008-682X.248809-26","first-page":"13\u201321","volume-title":"Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy","author":"Schulman","year":"2012","journal-title":"BJU Int"},{"key":"key-10.4103\/1008-682X.248809-27","first-page":"745\u201355","volume-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1008-682X.248809-28","first-page":"321\u20138","volume-title":"Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233)","author":"Anderson","year":"2013","journal-title":"Urol Int"},{"key":"key-10.4103\/1008-682X.248809-29","first-page":"342\u20138","volume-title":"The influence of androgen deprivation therapy on prostate size and voiding symptoms in prostate cancer patients in Korea","author":"Choi","year":"2016","journal-title":"Int Neurourol J"},{"key":"key-10.4103\/1008-682X.248809-30","first-page":"394\u2013402","volume-title":"Mechanisms involved in testosterone-induced relaxation to the pig urinary bladder neck","author":"Fernandes","year":"2012","journal-title":"Steroids"},{"key":"key-10.4103\/1008-682X.248809-31","first-page":"257\u201365","volume-title":"Long-term testosterone therapy improves urinary and sexual function, and quality of life in men with hypogonadism: results from a propensity matched subgroup of a controlled registry study","author":"Haider","year":"2018","journal-title":"J Urol"},{"key":"key-10.4103\/1008-682X.248809-32","first-page":"836\u201342","volume-title":"Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics","author":"Tombal","year":"2010","journal-title":"Eur Urol"}],"container-title":["Asian Journal of Andrology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:32:41Z","timestamp":1786732361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aja.aja_95_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"alternative-id":["248809"],"URL":"https:\/\/doi.org\/10.4103\/aja.aja_95_18","relation":{},"ISSN":["1008-682X"],"issn-type":[{"value":"1008-682X","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}